Sign in
ABIO Stock Price, Chart, Stats & News
ARCA biopharma, Inc.
Save
ABIO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -21.58% |
ROE | -25.30% |
D/E | 0.00x |
Interest coverage ratio | – |
ABIO valuation
P/E | – |
P/S | – |
P/B | 0.00x |
P/CF | -0.01x |
P/FCF | -0.39x |
P/OCF | -0.01x |
PEG | -0.00x |
EV multiple | -0.65x |
About
ARCA biopharma, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the creation and commercialization of genetically targeted therapies designed to address various cardiovascular ailments. The company's leading therapeutic programs feature two key candidates: Recombinant Nematode Anticoagulant Protein c2 (rNAPc2), known as AB201, which is currently being evaluated in a Phase IIb clinical trial for its potential in treating COVID-19. Gencaro (bucindolol hydrochloride), a distinctive pharmacogenetically-targeted beta-adrenergic receptor antagonist.
Similar securities
Based on sector and market capitalization
Report issue